Fulvestrant (Faslodex) for advanced breast cancer

被引：0
|
作者：
不详
机构：
来源：
MEDICAL LETTER ON DRUGS AND THERAPEUTICS | 2002年 / 44卷 / 1135期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：65 / 66
页数：2
相关论文
共 50 条
  • [21] Fulvestrant ('faslodex') as hormonal treatment in postmenopausal patients with advanced breast cancer progressing after treatment with tamoxifen and aromatase inhibitors.
    Perey, L
    Thurlimann, B
    Hawle, H
    Bonnefoi, H
    Aebi, S
    Pagani, O
    Goldhirsch, A
    Dietrich, D
    BREAST CANCER RESEARCH AND TREATMENT, 2002, 76 : S72 - S72
  • [22] Hormonal therapy for breast cancer:: Administration, patient education, and management of adverse events with fulvestrant (FASLODEX®).
    Versea, L
    Rosenzweig, M
    ONCOLOGY NURSING FORUM, 2004, 31 (02) : 408 - 409
  • [23] Fulvestrant ('Faslodex') in heavily pretreated postmenopausal patients with advanced breast cancer: single centre clinical experience from the compassionate use programme
    Mlineritsch, Brigitte
    Psenak, Oskar
    Mayer, Peter
    Moik, Martin
    Namberger, Konrad
    Hauser-Kronberger, Cornelia
    Greil, Richard
    BREAST CANCER RESEARCH AND TREATMENT, 2007, 106 (01) : 105 - 112
  • [24] Fulvestrant (Faslodex®) demonstrates clinical benefit in heavily pretreated postmenopausal women with advanced breast cancer:: a single-center experience.
    Franco, S
    Perez, A
    Tan-Chiu, E
    Frankel, C
    Vogel, C
    BREAST CANCER RESEARCH AND TREATMENT, 2003, 82 : S105 - S105
  • [25] Results of the German IPEP study evaluating the tolerability, efficacy, and acceptance of fulvestrant (FASLODEX®) under routine clinical conditions in advanced breast cancer
    Warm, M.
    Thomas, A.
    Ziegler, K.
    Kates, R.
    Overkamp, F.
    Harbeck, N.
    ONKOLOGIE, 2008, 31 : 52 - 53
  • [26] Fulvestrant (Faslodex®) versus anastrozole (Arimidex®) for the treatment of advanced breast cancer:: a prospective combined survival analysis of two multicenter trials.
    Pippen, J
    Osborne, CK
    Howell, A
    Robertson, JFR
    BREAST CANCER RESEARCH AND TREATMENT, 2003, 82 : S101 - S101
  • [27] Results of the German IPEP study evaluating the tolerability, efficacy, and acceptance of fulvestrant (Faslodex®) under routine clinical conditions in advanced breast cancer
    Warm, M.
    Thomas, A.
    Ziegler, K.
    Moers, C.
    Kates, R.
    Harbeck, N.
    EJC SUPPLEMENTS, 2008, 6 (07): : 127 - 127
  • [28] Fulvestrant in postmenopausal women with advanced breast cancer
    Bross, PF
    Baird, A
    Chen, G
    Jee, JM
    Lostritto, RT
    Morse, DE
    Rosario, LA
    Williams, GM
    Yang, PL
    Rahman, A
    Williams, G
    Pazdur, R
    CLINICAL CANCER RESEARCH, 2003, 9 (12) : 4309 - 4317
  • [29] Ribociclib plus Fulvestrant in Advanced Breast Cancer
    Hindie, Elif
    NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (23):
  • [30] Capivasertib plus fulvestrant in advanced breast cancer
    Lorenz, Judith
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2023, 83 (09) : 1057 - 1057
12345